Evidence map›Paper›PMID 41187580›Full record

ReviewImmunobiology2025

The grand escape - how pathogens outsmart the human complement system.

A A Nowacka, L Sordo Vieira, V Petr, B Fageräng, R Würzner, M Ohms

Abstract readReview
In one paragraph

Review in Immunobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

A A NowackaInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
L Sordo VieiraDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Florida, Gainesville, FL, United States of America.
V PetrDepartment of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
B FagerängDepartment of Immunology, University of Oslo, and Oslo University Hospital, Oslo, Norway; Department of Clinical Immunology, Rigshospitalet, and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
R WürznerInstitute of Hygiene & Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: reinhard.wuerzner@i-med.ac.at.
M OhmsInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany. Electronic address: mareike.ohms@uksh.de.

Funding

Mechanistic modeling of the innate immune responses of the human lung to understand the inter-individual heterogeneity of COVID-19 pneumoniaR01HL169974 · NHLBI · UNIVERSITY OF FLORIDA · PI REINHARD LAUBENBACHER, Borna Mehrad · 2023 to 2026
$2.9M
Tuning complement-mediated immunity in aspergillosis: a systems medicine approachK25AI175668 · NIAID · UNIVERSITY OF FLORIDA · PI Luis Alfonso Sordo Vieira · 2024 to 2026
$351k
NHLBI NIH HHS R01 HL169974NIAID NIH HHS K25 AI175668
6 · The paper itself

Abstract

Infectious diseases remain a significant cause of mortality and morbidity worldwide. Complement is a critical component in the defense against pathogens and despite their great differences, viruses, bacteria, fungi, and protists have all developed similar mechanisms of evasion from the human complement system. Using examples from four microbial groups (viruses, bacteria, fungi and protists), this review expands on examples of these different mechanisms of evasion. The mechanisms are grouped as (A) avoidance of recognition, (B) avoidance of eradication, (C) avoidance of activation and function, or (D) use of the complement proteins for entry into the host, in accordance with the classification initially proposed in 1999. Furthermore, this review will expand on novel descriptions of complement evasion, for example involving intracellular complement. Taken toge complement evasion is an essential tool used by pathogens not only in a defensive manner, protecting the pathogen from the host, but can also employed in an aggressive manner to aid the invasion of the host. Understanding these mechanisms has already influenced diagnostic and therapeutic tools, including vaccine development, and a further expansion of evasion molecules as biomarkers, vaccines or targets for therapy appears likely in the future.

Indexed as

Complement System ProteinsHost-Pathogen InteractionsImmune EvasionAnimalsComplement ActivationHumansComplement System ProteinsBiomarkersComplementImmune evasionInfectionPathogenTherapy

Identifiers

PMID41187580
PMCPMC13097072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.